Novartis has lifted the curtain on new data comparing the efficacy of Cosentyx (secukinumab) to Janssen’s Stelara (ustekinumab) in achieving skin clearance in patients with moderate-to-severe plaque psoriasis after 12 weeks.
Novartis debuts new data showing Cosentyx’s superiority over Janssen’s Stelara in psoriasis
